- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00373529
A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)
A Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients With Acute Myelogenous Leukemia (AML) for Whom Standard Induction Chemotherapy is Unlikely to be of Benefit
Clolar (clofarabine injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens.
This study will evaluate the efficacy of clofarabine in elderly patients with acute myelogenous leukemia (AML) who are unlikely to benefit from treatment with intensive chemotherapy regimens (cytarabine and anthracycline based regimens) used in younger patients with AML.
Przegląd badań
Status
Interwencja / Leczenie
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Arizona
-
Phoenix, Arizona, Stany Zjednoczone
- Mayo Clinical Hospital
-
Tucson, Arizona, Stany Zjednoczone
- Arizona Cancer Center
-
-
California
-
Los Angeles, California, Stany Zjednoczone
- USC/Norris Comprehensive Cancer Center and Hospital
-
San Diego, California, Stany Zjednoczone
- Scripps Cancer Center
-
-
Colorado
-
Denver, Colorado, Stany Zjednoczone
- Rocky Mountain Cancer Centers
-
-
Connecticut
-
Southington, Connecticut, Stany Zjednoczone
- Cancer Center of Central Connecticut
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone
- Emory University School of Medicine
-
Augusta, Georgia, Stany Zjednoczone
- Medical College of Georgia
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone
- Rush University Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone
- Beth Israel Deaconess Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone
- University of Michigan Comprehensive Cancer Center
-
-
New York
-
New York, New York, Stany Zjednoczone
- Mount Sinai School of Medicine
-
-
Oregon
-
Portland, Oregon, Stany Zjednoczone
- Oregon Health and Science University
-
-
Pennsylvania
-
Hershey, Pennsylvania, Stany Zjednoczone
- Penn State Hershey Medical Center
-
-
Tennessee
-
Nashville, Tennessee, Stany Zjednoczone
- Vanderbilt University Medical Center
-
-
Texas
-
Houston, Texas, Stany Zjednoczone
- University of MD Anderson Cancer Center
-
San Antonio, Texas, Stany Zjednoczone
- Cancer Care Centers of South Texas
-
-
Utah
-
Salt Lake City, Utah, Stany Zjednoczone
- University of Utah - Huntsman Cancer Institute
-
-
Washington
-
Seattle, Washington, Stany Zjednoczone
- Seattle Cancer Care Alliance
-
-
West Virginia
-
Morgantown, West Virginia, Stany Zjednoczone
- West Virginia University - HSC
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Diagnosis of AML (de novo, secondary or with an antecedent hematologic disorder [AHD])
- Age ≥ 60 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Presence of at least one adverse prognostic factor: Age ≥ 70 years; or AHD; or ECOG performance status of 2; or Intermediate or unfavorable (i.e., adverse) karyotype defined as any cytogenetic profile except the presence of any of the following:
- t(8;21)(q22;q22)
- inv(16)(p13;q22 or t(16;16)(p13;q22)
- t(15;17)(q22;q12) and variants.
- Adequate renal and hepatic function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN; and Serum creatinine ≤ 1.0 mg/dL; if serum creatinine > 1.0 mg/dL, then the estimated glomerular filtration rate (GFR) must be > 60 mL/min/1.73 m^2 as calculated by the Modification of Diet in Renal Disease (MDRD) equation
- Adequate cardiac function: left ventricular ejection fraction (LVEF) ≥ 40% or left ventricular fractional shortening ≥ 22%
Exclusion Criteria:
- Diagnosis of acute promyelocytic leukemia
- Prior treatment with clofarabine
- Prior treatment for AML or an antecedent hematologic disorder
- Prior hematopoietic stem cell transplant (HSCT)
- Prior radiation therapy to the pelvis
- Investigational agent received within 30 days prior to the first dose of study drug
- Ongoing uncontrolled systemic infection
- Diagnosis of another malignancy, unless the patient has been disease-free for at least 5 years following the completion of curative intent therapy with the following exceptions: Patients with treated non-melanoma skin cancer, in-situ carcinoma or cervical intraepithelial neoplasia regardless of disease-free duration are eligible for this study if definitive treatment for the condition has been completed; Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on PSA value are eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed
- Clinical evidence of central nervous system (CNS) involvement
- Severe concurrent medical condition or psychiatric disorder that would preclude study participation
- Positive human immunodeficiency virus (HIV) test
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Clofarabine
Participants received an induction cycle of clofarabine 30 mg/m^2/day intravenous infusion for 5 consecutive days.
Participants could then receive up to 5 additional cycles, repeated minimally every 28 days, of clofarabine 20 mg/m^2/day intravenous infusion for 5 consecutive days.
|
Induction cycle 1: cycle 1 of clofarabine 30 mg/m^2/day as a 1-hour intravenous infusion for 5 consecutive days. Reinduction (cycle 2) and/or Consolidation cycles (cycles 2-6): cycles repeated minimally every 28 days, of clofarabine 20 mg/m^2/day as a 1-hour intravenous infusion for 5 consecutive days.
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Percentage of Participants Achieving Overall Remission (OR) After No More Than Two Cycles (Approximately Month 2)
Ramy czasowe: approximately Month 2
|
Best response was assessed by the Independent Response Review Panel(IRRP) after two cycles of treatment.
Overall remission(OR) is the sum of complete remission(CR) and complete remission in the absence of platelet recovery(CRp).
CR includes normal values for peripheral blood cell counts (absolute neutrophil and platelet) and leukemic blast cells from bone marrow biopsy or aspirate, and absence of extramedullary disease.
Partial remission(PR) includes recovery of peripheral blood cells with improved but still abnormal values in leukemic blast cells.
|
approximately Month 2
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Kaplan Meier Estimate for Duration of Remission (DOR)
Ramy czasowe: Up to 2 years
|
DOR was defined as the number of days from achievement of OR as assessed by the Independent Response Review Panel (IRRP) until IRRP-determined disease recurrence or death (any cause), plus 1 day.
Participants who initiated alternative antileukemic treatment while in remission were censored on the date the therapy was initiated or on the date of last follow-up.
|
Up to 2 years
|
Kaplan Meier Estimate for Disease-free Survival (DFS)
Ramy czasowe: Up to 2 years
|
DFS was defined as the number of days from achievement of IRRP-determined overall response until IRRP-determined disease recurrence or death (any cause), regardless of intervening alternative antileukemic treatment, plus 1 day.
|
Up to 2 years
|
Kaplan Meier Estimates for Overall Survival (OS)
Ramy czasowe: Up to 2 years
|
OS was defined as the number of days from first dose of clofarabine until death for all participants, plus 1 day.
|
Up to 2 years
|
Overall Participant Counts Summarizing Adverse Events (AEs) During the Treatment and Follow-up Periods
Ramy czasowe: Up to 2 years
|
Participants with AEs that occurred during the treatment and follow-up periods. AEs were classified according to severity (graded using National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version 3.0) and relationship to study drug. Treatment emergent is defined as any event that either first presents after baseline or worsens in severity after baseline. NCI Common Terminology Criteria for Severity: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5= Death related to AE |
Up to 2 years
|
Percentage of Participants Who Died Within Thirty Days of Treatment (30-day Mortality Rate)
Ramy czasowe: up to Day 30
|
Percentage of participants who died within 30 days of the first dose of study drug, regardless of cause.
|
up to Day 30
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Number of Participants Achieving Overall Remission After A Maximum of Two Cycles by Subgroup of Baseline Prognostic Factors
Ramy czasowe: approximately Month 2
|
The number of participants within each subgroup of baseline prognostic factors of the full analysis set who achieved a best response of either a complete response (CR) or a complete response in the absence of platelet recovery (CRp) as determined by the Independent Response Review Panel following a maximum of two cycles of treatment.
|
approximately Month 2
|
Współpracownicy i badacze
Sponsor
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- CLO24300606
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Ostra białaczka szpikowa
-
Lundquist Institute for Biomedical Innovation at...RekrutacyjnyDługodystansowy COVID lub Post Acute Sequella COVID - PASC (U09.9)Stany Zjednoczone
-
Intermountain Health Care, Inc.Regeneron PharmaceuticalsJeszcze nie rekrutacjaPost-acute COVID-19 (PACS) lub zespół „długiego COVID-19”.Stany Zjednoczone
-
Dana-Farber Cancer InstituteBrigham and Women's HospitalZakończonyOporna na leczenie ostra białaczka szpikowa | Zespół mielodysplastyczny RAEB-I lub RAEB-II | Oporny na leczenie CML Myeloid Blast CrisisStany Zjednoczone
Badania kliniczne na clofarabine
-
Istituto Giannina GasliniZakończony